Alamar Biosciences

ALMR

Precision medicineBiotech & pharmaceuticalsHealthcare diagnostics

$25.28vs prev close▼-2.14(-7.80%)

$18.8552W Range$39.61

31% from low

-3.47 (-12.07%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

2 buys

Concentrated buys

1M net buy

+$3.2M

≈ +132K shares

Portfolio Weight

0.22%

1M -0.01%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +1.3% · Market value +26.3% · Weight -0.01%p

Trade Intensity

Minor adjustment

Trade Log2-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.12	BUY	ARKG	101,154	$24.24	$2.5M
26.10.09	BUY	ARKG	31,068	$25.27	$785.1K
26.07.16	BUY	ARKG	37,822	$24.95	$943.7K
26.07.15	BUY	ARKG	29,223	$26.13	$763.6K
26.07.14	BUY	ARKG	10,424	$27.05	$282.0K
26.07.13	BUY	ARKG	37,003	$27.40	$1.0M
26.07.10	BUY	ARKG	1,991	$28.42	$56.6K
26.07.09	BUY	ARKG	676	$26.48	$17.9K
26.07.08	BUY	ARKG	20,644	$25.30	$522.3K
26.07.07	BUY	ARKG	18,183	$25.23	$458.8K
26.07.06	BUY	ARKG	37,947	$25.66	$973.7K
26.07.02	BUY	ARKG	12,996	$25.94	$337.1K
26.07.01	BUY	ARKG	83,891	$26.13	$2.2M
26.06.30	BUY	ARKG	18,829	$27.09	$510.1K
26.06.29	BUY	ARKG	2,390	$27.77	$66.4K

10.12BUY

101,154

ARKGClose$24.24Est. total$2.5M

10.09BUY

31,068

ARKGClose$25.27Est. total$785.1K

07.16BUY

37,822

ARKGClose$24.95Est. total$943.7K

07.15BUY

29,223

ARKGClose$26.13Est. total$763.6K

07.14BUY

10,424

ARKGClose$27.05Est. total$282.0K

07.13BUY

37,003

ARKGClose$27.40Est. total$1.0M

07.10BUY

1,991

ARKGClose$28.42Est. total$56.6K

07.09BUY

676

ARKGClose$26.48Est. total$17.9K

07.08BUY

20,644

ARKGClose$25.30Est. total$522.3K

07.07BUY

18,183

ARKGClose$25.23Est. total$458.8K

07.06BUY

37,947

ARKGClose$25.66Est. total$973.7K

07.02BUY

12,996

ARKGClose$25.94Est. total$337.1K

07.01BUY

83,891

ARKGClose$26.13Est. total$2.2M

06.30BUY

18,829

ARKGClose$27.09Est. total$510.1K

06.29BUY

2,390

ARKGClose$27.77Est. total$66.4K

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

1,021,222

Portfolio Weight

0.22%

in ETF 1.6%

Est. Value

$39M

30D Net

+$3M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$35.40

vs Current ▲ +29.1% upside

Current$27.42

Low ~ High$31.00 ~ $45.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Stifel

Buy

$32.00

+16.70%

$36.57

Maintain

2026-08-11

JP Morgan

Overweight

$35.00

+27.64%

$36.57

Maintain

2026-08-11

Leerink Partners

Outperform

$35.00

+27.64%

$22.97

Upgrade

2026-05-12

TD Cowen

Buy

$30.00

+9.41%

$22.97

Upgrade

2026-05-12

JP Morgan

Overweight

$30.00

+9.41%

$22.97

Upgrade

2026-05-12

1 / 2

Avg Target

$35.40

vs Current ▲ +29.1% upside

Buy

5 analysts

Strong Buy 1Buy 3Hold 1

Low $31.00

Current $27.42

High $45.00

Firm	Position	Target	Upside	Close	Action	Date
Stifel	Buy	$32.00	+16.70%	$36.57	Maintain	26.08.11
JP Morgan	Overweight	$35.00	+27.64%	$36.57	Maintain	26.08.11
Leerink Partners	Outperform	$35.00	+27.64%	$22.97	Upgrade	26.05.12
TD Cowen	Buy	$30.00	+9.41%	$22.97	Upgrade	26.05.12
JP Morgan	Overweight	$30.00	+9.41%	$22.97	Upgrade	26.05.12

1 / 2

Price Information

Previous Close$27.42

Open$27.37

Day Range$25.15 - $27.57

52-Week Range$18.85 - $39.61

1-Year Change24.64%

Trading Volume

Volume456,178

Avg Volume (3mo)459,898

Valuation

Market Cap1.8B

Book Value$4.51

Shares Outstanding69,392,766

Financials

Revenue (TTM)100.4M

Net Income-49,661,000

EPS$-1.20

EBITDA-37,483,000

Profitability

P/E Ratio-

P/B Ratio5.61

Return on Equity (ROE)-

Return on Assets (ROA)-

Profit Margin-49.45%

EV/EBITDA-45.46

Beta-

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)37.53

Company Overview

Alamar Biosciences is a proteomics company specializing in high-sensitivity protein biomarker analysis for research and early disease detection. Their core offerings include the NULISA platform for ultra-sensitive biomarker detection and the ARGO HT system for high-throughput biomarker profiling, supported by cloud-based analytics and specialized assays for neurodegenerative diseases. Alamar serves academic and industry researchers with its advanced proteomics solutions.

P/B

5.61

High valuation

ROE

Return on Equity

Beta

Market Volatility

RSI(14)

37.5

Neutral zone

AI-generated summary. Not investment advice.

Alamar Biosciences

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks